Plasma HIV viral rebound following protocol-indicated cessation of ART commenced in primary and chronic HIV infection

Plasma HIV viral rebound following protocol-indicated cessation of ART commenced in primary and chronic HIV infection

OBJECTIVES: The magnitude of HIV viral rebound following ART cessation has consequences for clinical outcome and onward transmission. We compared plasma viral load (pVL) rebound after stopping ART initiated in primary (PHI) and chronic HIV infection (CHI). DESIGN: Two populations with protocol-indic...

Full description

Bibliographic Details
Main Authors:	Hamlyn, E, Ewings, F, Porter, K, Cooper, D, Tambussi, G, Schechter, M, Pedersen, C, Okulicz, J, McClure, M, Babiker, A, Weber, J, Fidler, S, Phillips, R
Format:	Journal article
Language:	English
Published:	Public Library of Science 2012

Similar Items

Plasma HIV viral rebound following protocol-indicated cessation of ART commenced in primary and chronic HIV infection.
by: Elizabeth Hamlyn, et al.
Published: (2012-01-01)

Duration of HIV-1 viral suppression on cessation of antiretroviral therapy in primary infection correlates with time on therapy
by: Stöhr, W, et al.
Published: (2013)

Duration of HIV-1 viral suppression on cessation of antiretroviral therapy in primary infection correlates with time on therapy.
by: Wolfgang Stöhr, et al.
Published: (2013-01-01)

Immunological biomarkers predict HIV-1 viral rebound after treatment interruption
by: Hurst, J, et al.
Published: (2015)

Short-course antiretroviral therapy in primary HIV infection.
by: Fidler, S, et al.
Published: (2013)

Protective HLA class I alleles are associated with reduced immune activation and fibrinolysis in individuals with primary HIV infection
by: Hamlyn, E, et al.
Published: (2010)

HIV-1-specific CD4+ T lymphocyte turnover and activation increase upon viral rebound.
by: Scriba, T, et al.
Published: (2005)

HIV-1-specific CD4+ T lymphocyte turnover and activation increase upon viral rebound.
by: Scriba, T, et al.
Published: (2005)

HIV-1 Specific CD4 Responses in Primary HIV-1 Infection predict disease progression in the SPARTAC Trial
by: Frater, A, et al.
Published: (2013)

Increased levels of CD4 T-cell activation in individuals with CXCR4 using viruses in primary HIV-1 infection.
by: Hamlyn, E, et al.
Published: (2012)

Slower CD4 cell decline following cessation of a 3 month course of HAART in primary HIV infection: findings from an observational cohort.
by: Fidler, S, et al.
Published: (2007)

Viral Rebound Kinetics Correlate with Distinct HIV Antibody Features
by: Bartsch, Yannic C, et al.
Published: (2021)

Viral Rebound Kinetics Correlate with Distinct HIV Antibody Features
by: Yannic C. Bartsch, et al.
Published: (2021-04-01)

HIV Antibody Fc N-Linked Glycosylation Is Associated with Viral Rebound
by: Offersen, Rasmus, et al.
Published: (2021)

HIV Antibody Fc N-Linked Glycosylation Is Associated with Viral Rebound
by: Rasmus Offersen, et al.
Published: (2020-12-01)

HIV-1 resistance genotyping by sequencing produces inconsistent results for mixed viral populations.
by: Frater, A, et al.
Published: (2000)

Impact of antiretroviral therapy in primary HIV infection on natural killer cell function and the association with viral rebound and HIV DNA following treatment interruption
by: Matthew Pace, et al.
Published: (2022-08-01)

11 Murine model to predict viral rebound in HIV+ allotransplanted subjects
by: Maria Salgado, et al.
Published: (2017-07-01)

HIV-1 DNA predicts disease progression and post-treatment virological control.
by: Williams, J, et al.
Published: (2014)

Risk of HIV viral rebound in HIV infected patients on direct acting antivirals (DAAs) treatment for HCV.
by: Giulia Morsica, et al.
Published: (2022-01-01)

Rebound of plasma viremia following cessation of antiretroviral therapy despite profoundly low levels of HIV reservoir: implications for eradication.
by: Le, T, et al.
Published: (2011)

Predictions of time to HIV viral rebound following ART suspension that incorporate personal biomarkers.
by: Jessica M Conway, et al.
Published: (2019-07-01)

Multidrug-resistant HIV viral rebound during early syphilis: a case report
by: Andrea Giacomelli, et al.
Published: (2020-04-01)

Impact of CD4 and CD8 dynamics and viral rebounds on loss of virological control in HIV controllers.
by: Fanny Chereau, et al.
Published: (2017-01-01)

Factors affecting commencement and cessation of smoking behaviour in Malaysian adults
by: Ghani, W.M., et al.
Published: (2012)

Factors affecting commencement and cessation of smoking behaviour in Malaysian adults
by: Ghani Wan, et al.
Published: (2012-03-01)

HIV clearance in infants.
by: McClure, M, et al.
Published: (1996)

The cell biology of HIV-1 latency and rebound
by: Uri Mbonye, et al.
Published: (2024-04-01)

Prolonged administration of maraviroc reactivates latent HIV in vivo but it does not prevent antiretroviral-free viral rebound
by: María Rosa López-Huertas, et al.
Published: (2020-12-01)

4 Post-treatment control or treated controllers? The impact of ART on time to viral rebound in recent seroconverters
by: G.E. Martin, et al.
Published: (2016-07-01)

The role of the gut mucosa in protection from HIV-1 in highly exposed persistently seronegative individuals (HEPS)
by: Fox, J, et al.
Published: (2009)

Factors affecting commencement and cessation of betel quid chewing behaviour in Malaysian adults.
by: Ghani, W.M., et al.
Published: (2011)

Factors affecting commencement and cessation of betel quid chewing behaviour in Malaysian adults.
by: Ghani, W.M., et al.
Published: (1990)

Factors affecting commencement and cessation of betel quid chewing behaviour in Malaysian adults
by: Handa Yujiro, et al.
Published: (2011-02-01)

Phylogenetic analysis consistent with a clinical history of sexual transmission of HIV-1 from a single donor reveals transmission of highly distinct variants.
by: English, S, et al.
Published: (2011)

HIV-1 DNA predicts disease progression and post-treatment virological control
by: James P Williams, et al.
Published: (2014-09-01)

HIV patients' perceptions of a potential multi-component mindfulness-based smoking cessation smartphone application intervention.
by: Taghrid Asfar, et al.
Published: (2022-01-01)

HIV envelope antibodies and TLR7 agonist partially prevent viral rebound in chronically SHIV-infected monkeys.
by: Brian Moldt, et al.
Published: (2022-04-01)

Factors associated with viral suppression and rebound among adult HIV patients on treatment: a retrospective study in Ghana
by: Stephen Opoku, et al.
Published: (2022-05-01)

HIV viral suppression and risk of viral rebound in patients on antiretroviral therapy: a two- year retrospective cohort study in Northern Tanzania
by: Monica S Kahabuka, et al.
Published: (2024-04-01)